However, before performing the Luminex analysis, we examined antibody reactivity by ELISA with peptide A1 (DbpA residues 1 to 18) in more detail, as a peptide spanning residues 6 to 30 was recognized by sera from patients clinically diagnosed as having erythema migrans (EM), an early manifestation of Lyme disease (28). This evidence concerns the gene YBX3 and erythema multiforme.